RNA splicing factor Rbm25 underlies heterogeneous preleukemic clonal expansion in mice.
Charles BramlettJiya EerdengDu JiangYeachan LeeIvon GarciaMary C Vergel-RodriguezPatrick CondieAnna NogalskaRong LuPublished in: Blood (2023)
Clonal expansion sets the stage for cancer genesis by allowing for the accumulation of molecular alterations. While genetic mutations that induce clonal expansion and malignancy, such as Tet2, have been identified, these mutations are also frequently found in healthy individuals. Here, we tracked preleukemic clonal expansion using genetic barcoding in an inducible Tet2 knockout mouse model and found that only a small fraction of hematopoietic stem cells (HSCs) expanded excessively upon Tet2 knockout. These overexpanded HSCs expressed significantly lower levels of genes associated with leukemia and RNA splicing compared to non-overexpanded Tet2 knockout HSCs. Knocking down Rbm25, an identified RNA splicing factor, accelerated the expansion of Tet2-knockout hematopoietic cells in vitro and in vivo. Our data suggest that mutations of an epigenetic factor Tet2 induces variability in the expression of an RNA splicing factor Rbm25, which subsequently drives heterogeneous preleukemic clonal expansion. This heterogeneous clonal expansion could contribute to the variable disease risks across individuals.
Keyphrases
- stem cells
- mouse model
- bone marrow
- poor prognosis
- induced apoptosis
- type diabetes
- dna methylation
- genome wide
- acute myeloid leukemia
- squamous cell carcinoma
- wild type
- nucleic acid
- long non coding rna
- electronic health record
- big data
- copy number
- papillary thyroid
- binding protein
- climate change
- mesenchymal stem cells
- data analysis
- human health